

CARB-X Antibacterial Treatment and Prevention Product Portfolio 2020.08.011

Sponsor	Product	Novelty			Description	Priority		Development Stage			
		New Abx Class	Non-traditional Product	New Target		CDC	WHO	Hit to Lead	Lead Optimization	Pre-Clinical	Phase I
Amicrube	Amicidin-β		✓		Next-generation local antimicrobial	✓	✓			Broad spectrum	
Antabio	PEI		✓	✓	Pseudomonas elastase inhibitor	✓	✓			<i>P. aeruginosa</i>	
BB100, LLC (Bravos)	BB100		✓	✓	Monoclonal Antibody	✓	✓			<i>Escherichia coli</i>	
BioVerisy	AVATAR-SA		✓	✓	Anti-virulence agent	✓	✓			<i>S. aureus</i> & MRSA	
Bigworks Research	GYROX	✓			Gyrase-topoisomerase inhibitor	✓	✓			Gram-negative activity	
Centauri Therapeutics	ABX01		✓		Dual-acting large molecule	✓	✓			Gram-negative activity	
ContraFect	Gram-negative gramins	✓			Phage-encoded lytic peptide	✓	✓			Gram-negative activity	
ContraFect	Gram-negative lysins		✓	✓	Recombinant lytin protein	✓	✓			<i>P. aeruginosa</i>	
Debiopharm International SA	Debio1453	✓		✓	Narrow-spectrum inhibitors of FabI	✓	✓			<i>Neisseria gonorrhoeae</i>	
Debiopharm International SA	Debio1454	✓		✓	Narrow-spectrum inhibitors of FabI	✓	✓			<i>Acinetobacter baumannii</i>	
Eligo Bioscience	EB004		✓		CRISPR-based bacteriophage therapeutic	✓	✓			Gram-negative activity	
Entasis Therapeutics	ETX0282CPD P				Oral Gram-negative combination	✓	✓			Gram-negative activity	
Entasis Therapeutics	Non-BL PBPI	✓			Non-beta-lactam PBPI	✓	✓			Gram-negative activity	
Evotec SE	TRIBE Antibiotics	✓			Novel Direct Acting Broad Spectrum	✓	✓			Gram-negative activity	
Facile Therapeutics	EBSELEN		✓	✓	Prevention of <i>C. difficile</i> Recurrence	✓	✓			<i>C. difficile</i>	
Forge Therapeutics	FG-1pxC-LUNG	✓		✓	LpxC inhibitor	✓	✓			<i>P. aeruginosa</i>	
Forge Therapeutics	FG-1pxC-UTI	✓		✓	LpxC inhibitor	✓	✓			Gram-negative activity	
Idorsia	TopESKAPE	✓			Dual-acting topoisomerase inhibitor	✓	✓			<i>Acinetobacter</i> , <i>Pseudomonas</i> , & <i>Enterobacteriaceae</i>	
Integrated BioTherapeutics	IBT-V02		✓		Multi-valent toxoid vaccine	✓	✓			<i>S. aureus</i>	
Lytica Therapeutics	SIAMPS	✓	✓		Large molecule direct-acting therapeutic	✓	✓			Gram-negative pathogens	
Microbion	Novel bismuth thiol	✓		✓	Pravibismine suspension for inhalation	✓	✓			<i>P. aeruginosa</i> , <i>S. aureus</i> , MRSA	
Microbiotix	Trans-Translation Inhibitors		✓	✓	Oral antibiotic	✓	✓			MDR N. gonorrhoea	
Microbiotix	T3SS inhibitor		✓	✓	Virulence modifier	✓	✓			<i>P. aeruginosa</i>	
MicRx	MRX-8				Soft drug polymyxin	✓	✓			Gram-negative activity	
Oxford Drug Design	DaaRSi	✓		✓	Dual-target Aminoglycoside Synthetase Inhibitor	✓	✓			Gram-negative activity	
Peptilogics	PLG0206	✓			Direct-acting engineered peptides	✓	✓			Broad Spectrum	
Polyphor	OMPTA PCL7306	✓		✓	Novel class, MDR/MDR ESKAPE	✓	✓			Gram-negative activity	
Seres Therapeutics	SER-155		✓		Microbiome-transplant patients	✓	✓			Broad spectrum activity vs CRE/VRE	
Summit Therapeutics	SMT-571 Series	✓		✓	Novel class, orally active antibiotic	✓	✓			<i>Neisseria gonorrhoeae</i>	
Taxis Pharmaceuticals	EPI-PA			✓	Efflux Pump Inhibitor	✓	✓			<i>P. aeruginosa</i>	
Techulon	PPNA-XPA	✓	✓	✓	Peptide-peptide nucleic acids (PPNA)s	✓	✓			<i>A. baumannii</i> & <i>P. aeruginosa</i>	
Vaxdyn	KAPAVAX				Trivalent vaccine to prevent bacterial pneumonia					Gram-negative activity	
Trellis Bioscience	TRL1068		✓	✓	Monoclonal antibody	✓	✓			Broad spectrum	
University of Queensland	OCTAPEPTIN ABX	✓			Engineered peptides	✓	✓			Gram-negative activity	
Vaxxte (formerly SutroVax, Inc.)	GAS vaccine		✓	✓	Carbohydrate conjugate vaccine	✓	✓			<i>Streptococcus pyogenes</i>	
Vaxxion AG	VXN-319		✓	✓	Semi-synthetic conjugate vaccine	✓	✓			<i>K. pneumoniae</i>	
Vedanta	VE707		✓		Microbiome	✓	✓			CRE-ESBLs	
Venatorx	04CARB-X 0652	✓			Oral cyclic-boronate HRP inhibitor	✓	✓			<i>Neisseria gonorrhoeae</i>	
Zikani (formerly Macrolides)	Novel Macrolides				Novel macrolide antibiotics with Gram-negative activity	✓	✓			Gram-negative activity	

CARB-X Antibacterial Diagnostic Product Portfolio

Sponsor	Type	Technology	Description			
			Feasibility	Optimization	Development	Verification and Validation
Day Zero Diagnostics	ID & AST	Whole genome sequencing & machine learning	Drug resistant Pathogens			
Helixbind	Hospital-Based Dx	Automated culture-free pathogen ID			Bloodstream Infections	
Module Innovations	ID & AST	ASTENSE ID/AST	UTIs			
Pattern Bioscience	Hospital-Based Dx	Digital Culture Single cell biometric analysis		RTIs, UTIs, BSIs		
Proteus	Hospital-Based Dx	Optical bacterial imaging		Respiratory Tract Infections		
Talis	Near-Patient Dx	qLAMP for Pathogen ID; qLAMP for Phenotypic AST	AST for <i>Neisseria gonorrhoeae</i> ; ID for <i>Neisseria gonorrhoeae</i> and <i>Chlamydia trachomatis</i>			

The above projects are Powered by CARB-X utilizing non-dilutive funding from BARDA, Wellcome Trust, Germany's Federal Ministry of Education and Research (BMBF), and NIAID, with some funding for specific projects from the UK Government's Global Antimicrobial Resistance Innovation Fund (GARIF) and the Bill & Melinda Gates Foundation. Characterizations of new Abx Class and New Target are by CARB-X, following Pew pipeline analysis: <http://www.pewtrusts.org/en/multimedia/data-visualizations/2014/antibiotics-currently-in-clinical-development>. Other characterizations by CARB-X experts and external expert opinion. Abx = traditional small molecule antibiotic. Non-traditional Product = not a traditional small molecule antibiotic.